
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a promising financial outlook driven by its innovative 3D bioprinting technology, particularly the rhCollagen-based bioink Collink.3D, which has shown superior performance in structured tissue formation compared to traditional materials. The recently operational U.S.-based logistics center is poised to enhance sales for both the BioInk and rhCollagen products, suggesting potential growth in revenue as adoption by research institutions increases. Additionally, strategic partnerships, including one with Allergan for dermal and soft tissue fillers, combined with upcoming clinical developments, highlight CollPlant's competitive edge in the regenerative medicine market and its relevance in advanced tissue engineering.
Bears say
CollPlant Biotechnologies Ltd's recent $2.0 million registered direct financing has raised concerns regarding its ability to effectively capitalize on favorable market conditions, thereby potentially undermining investor confidence. The pricing of shares at $1.25 suggests persistent downward pressure on the equity, limiting the company's capacity for future capital formation. Furthermore, lowered expectations for key product lines such as Dermal Fillers and BioInk, along with the removal of the Breast Implants program from financial forecasts, reflect a cautious outlook on revenue generation prospects.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares